Primary biliary cholangitis, or PBC, is an autoimmune liver disease that can cause liver failure and death. In this test-specific episode of the "Answers From the Lab" podcast, Anne Tebo, Ph.D., Co-Laboratory Director of the Antibody Immunology Laboratory and Professor at DLMP, Mayo Clinic, explains how Mayo Clinic Laboratories' new testing expands the options for diagnosing PBC.

The presence of anti-mitochondrial antibodies or AMA is hallmark feature of PBC. However, a subset of PBC patients are seronegative for AMA and testing for the PBC-specific autoantibodies, anti-Sp100 and anti-gp210 antibodies may be useful in their evaluation. Mayo Clinic Laboratories has launched new ELISA serum tests that identify antibodies to Sp100 and GP210 — two other antibodies associated with PBC — in AMA-negative patients. The tests can be ordered individually (Test IDs: SP100 and GP210) or together in a new PBC panel (Test ID: PBC2).

"Testing for SP100 and GP210 antibodies, in addition to AMA, is recommended for all patients with suspicion for PBC. This is really an appropriate standard of care," Dr. Tebo says.

Mayo Clinic Laboratories' new PBC Antibody Panel (Test ID: PBCPN) evaluates at-risk or previously diagnosed PBC patients with new features of other liver or autoimmune diseases. It covers AMA, Sp100, GP210, and two indirect fluorescent antibodies.

"The comprehensive panel provides an optimal approach, as it has the potential to support the diagnosis of AMA-positive and -negative PBC patients, as well as identify patients with coexisting systemic autoimmune diseases," Dr. Tebo says.

Listen to learn more about Mayo Clinic Laboratories' SP100, PBCPN, PBC2, and GP210 testing.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

PBCPN  | Primary Biliary Cholangitis Antibody Panel, Serum

PBC2   | SP100 and GP210 Antibodies, IgG, Serum

SP100   | SP100 Antibody, IgG, Serum

GP210   | GP210 Antibody, IgG, Serum

The latest

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

April 30, 2024

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.

April 16, 2024

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

View MoreView Less